ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Apontis Pharma AG's annualizedNet Income for the quarter that ended in Jun. 2025 was €1.21 Mil.
Apontis Pharma AG's average Total Assets over the quarter that ended in Jun. 2025 was €44.18 Mil. Therefore, Apontis Pharma AG's annualized ROA % for the quarter that ended in Jun. 2025 was 2.73%.
The historical rank and industry rank for Apontis Pharma AG's ROA % or its related term are showing as below:
FRA:APPH'
s ROA % Range Over the Past 10 Years
Min: -19.27 Med: -2.86 Max: 4.72
Current: 1.44
During the past 7 years, Apontis Pharma AG's highest ROA % was 4.72%. The lowest was -19.27%. And the median was -2.86%.
FRA:APPH's ROA % is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.685
vs FRA:APPH: 1.44
Apontis Pharma AG (FRA:APPH) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Jun. 2025) net income data. The Revenue data used here is two times the semi-annual (Jun. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Apontis Pharma AG ROA % Related Terms
Apontis Pharma AG ROA % Historical Data
* Premium members only.
The historical data trend for Apontis Pharma AG's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apontis Pharma AG ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's ROA % distribution charts can be found below:
* The bar in red indicates where Apontis Pharma AG's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Jun. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Apontis Pharma AG (FRA:APPH) has a ROA % of 2.73% as of Jun. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Apontis Pharma AG and its competitors.
Is Apontis Pharma AG's ROA % too high?
Apontis Pharma AG's current ROA % is 2.73%. The Drug Manufacturers industry median ROA % is 2.69. Apontis Pharma AG's value of 2.73% is 1.7% above this industry median. Overall, Apontis Pharma AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Apontis Pharma AG's ROA % compare to ZTS and UTHR?
Apontis Pharma AG's ROA % of 2.73% can be compared against companies in the Drug Manufacturers industry. The industry median ROA % is 2.69. Apontis Pharma AG's value of 2.73% is 1.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apontis Pharma AG's current ROA % of 2.73% is 1.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Apontis Pharma AG and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apontis Pharma AG's current ROA % is 2.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apontis Pharma AG stock overvalued right now?
Apontis Pharma AG (FRA:APPH) has a current ROA % of 2.73%. The stock's GF Value™ is €10.46, compared to a current price of €11.00 — trading 5.2% above its estimated fair value. The current ROA % is 2.73% and 1.7% above the Drug Manufacturers industry median of 2.69. Apontis Pharma AG's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Apontis Pharma AG (FRA:APPH), the current ROA % is 2.73% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?
Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued.
The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.
Key valuation signals for FRA:APPH:
ROA %: 2.73%
GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
Industry Position: 1.7% above the Drug Manufacturers median
No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score
Get the complete analysis for FRA:APPH
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APPH has been successfully added to your 
